<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356352</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00063576</org_study_id>
    <nct_id>NCT04356352</nct_id>
  </id_info>
  <brief_title>Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain</brief_title>
  <official_title>A Comparison of Lidocaine, Esmolol, and Placebo Without Use of a Tourniquet for Relieving Pain From Intravenous Administration of Propofol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis is that esmolol and lidocaine, when given without the use of a
      tourniquet, provide relief of propofol injection pain that is superior to placebo when
      assessed using the propofol pain scoring tool
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three arms: lidocaine, esmolol, and placebo. Eligible patients will be
      18-60 years old, ASA physical status 1-3, and scheduled for an elective surgical procedure.
      Patients will be randomized to receive lidocaine, esmolol, or placebo. Both the patients and
      the administering/observing providers will be blinded to the study drug or placebo being
      administered
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>subjects randomized to receive either lidocaine, esmolol, or placebo immediately prior to the administration of propofol for their surgical procedure to treat injection site pain caused by propofol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>assessor asking for pain scores will be blinded from the randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain with propofol injection</measure>
    <time_frame>following administration of a sub-induction dose of propofol, 0.5 mg/kg up to 50 mg, just prior to full induction</time_frame>
    <description>the proportion of patients with pain using a pain scoring system previously used by studies looking at various remedies to decrease propofol injection pain In this scoring system, patients are observed and their responses and behaviors are rated according a specific rubric (Table 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>vital signs each minute for the first 10 minutes following induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>vital signs each minute for the first 10 minutes following induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>vital signs each minute for the first 10 minutes following induction</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Injection Site Irritation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg/kg lidocaine to a max of 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg/kg esmolol to a max of 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-60 years of age

          -  ASA 1-3

          -  Elective surgical procedure

        Exclusion Criteria:

          -  BMI â‰¥ 45

          -  Pregnancy

          -  Requirement for RSI or awake intubation

          -  Suspected or known difficult airway

          -  Contraindication to IV in either upper extremity

          -  Chronic pain syndrome including fibromyalgia

          -  Use of opioids, NSAIDs, or other analgesics within 24 hours (including preoperative PO
             Celebrex, Lyrica, Tylenol, etc.)

          -  Any use of opioids in the past three months

          -  Significant cardiopulmonary or hepatic dysfunction

          -  Hypersensitivity to study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Norton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Norton, MD</last_name>
    <phone>336-716-4498</phone>
    <email>mnorton@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynnette Harris, BSN</last_name>
    <phone>336-716-8791</phone>
    <email>lcharris@wakehealth.edu</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

